Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maint...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Книга |
| Опубліковано: |
Adis, Springer Healthcare,
2023-07-01T00:00:00Z.
|
| Предмети: | |
| Онлайн доступ: | Connect to this object online. |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Інтернет
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Примірник 1 | Доступно |